Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 341,900,896
  • Shares Outstanding, K 2,693,830
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.79
  • Price/Sales 4.78
  • Price/Cash Flow 15.41
  • Price/Book 4.91

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.34 +3.74%
on 05/11/17
128.37 -1.13%
on 05/16/17
+3.41 (+2.76%)
since 04/26/17
3-Month
120.95 +4.94%
on 04/18/17
129.00 -1.61%
on 03/15/17
+4.19 (+3.41%)
since 02/24/17
52-Week
109.32 +16.10%
on 12/07/16
129.00 -1.61%
on 03/15/17
+14.02 (+12.42%)
since 05/26/16

Most Recent Stories

More News
Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

JNJ : 126.92 (-0.48%)
MRK : 64.92 (-0.18%)
AMGN : 155.01 (-0.27%)
PFE : 32.14 (-0.06%)
Drugmaker paying $33M over recalled nonprescription meds

TRENTON, N.J. (AP) — Johnson & Johnson has reached a $33 million settlement with 42 states, resolving allegations the health care giant sold nonprescription medicines that didn't meet federal quality...

JNJ : 126.92 (-0.48%)
Xarelto Lawsuit Filings Exceed 18,000, as Second Bellwether Trial Set to Get Underway, Bernstein Liebhard LLP Reports

Xarelto patients who suffered internal bleeding and other life-threatening complications allegedly related to use of the medication continue to file lawsuits in courts throughout the U.S. According to...

JNJ : 126.92 (-0.48%)
Havas Group Acquires Sorento, An India-based Health-and-Wellness Communications Agency

Havas Group is expanding its capabilities and footprint in the important and burgeoning Indian market by adding Sorento to its roster of agencies. Sorento will integrate the Havas Health & You business...

JNJ : 126.92 (-0.48%)
Innovative Targeting Solutions Collaboration with Janssen Biotech Achieves Multiple Milestones

Innovative Targeting Solutions Inc. (ITS) today announced the successful achievement of three milestones from its collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies...

JNJ : 126.92 (-0.48%)
Almost There

Almost There

PPC : 23.53 (+1.29%)
AAOI : 71.51 (+5.35%)
CG : 17.75 (+0.57%)
CI : 161.32 (-0.20%)
JNJ : 126.92 (-0.48%)
UCTT : 24.11 (+4.33%)
AEIS : 77.46 (+0.87%)
KBH : 21.32 (+0.09%)
YUM : 72.09 (-0.06%)
PAH : 12.65 (+0.48%)
PFGC : 28.35 (-0.35%)
WTW : 27.10 (-0.26%)
YUMC : 37.76 (-0.05%)
CVGW : 68.45 (+0.88%)
HUBS : 70.95 (+0.57%)
Risperdal Lawsuits Continue to Plague Johnson & Johnson, With More Than 16,000 Filings Nationwide, Bernstein Liebhard LLP Reports

Johnson & Johnson and its Janssen Pharmaceuticals subsidiary continue to face legal claims over gynecomastia and other side effects allegedly associated with Risperdal. According to a May 8th filing with...

JNJ : 126.92 (-0.48%)
Hepatitis Therapeutics Market to Reach $25.8 Billion by 2025 - Key Players are Gilead, Merck, Johnson & Johnson, Bristol-Myers Squibb Company & AbbVie - Research and Markets

Research and Markets has announced the addition of the "Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America,...

JNJ : 126.92 (-0.48%)
MRK : 64.92 (-0.18%)
BMY : 53.97 (-0.77%)
Cooler Heads, Smaller Losses

Cooler Heads, Smaller Losses

DE : 122.79 (+0.29%)
UVXY : 10.95 (-3.35%)
JNJ : 126.92 (-0.48%)
IOO : 85.68 (-0.10%)
CSX : 53.96 (+0.32%)
USCR : 66.95 (-1.47%)
VC : 100.26 (+0.56%)
ACCO : 11.25 (unch)
TVIX : 23.82 (-3.37%)
AMC : 24.70 (+5.56%)
WDC : 90.01 (+0.83%)
PLCE : 106.65 (-0.42%)
NUE : 58.15 (-0.38%)
WMT : 78.13 (-0.23%)
Operation Smile's 35th Anniversary presented by Johnson & Johnson

Wednesday night, New York's top philanthropists, celebrities and supporters gathered in Chelsea for an evening honoring the work of famed photographer Brian Bowen Smith in commemoration of Operation Smile's...

JNJ : 126.92 (-0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 127.98
1st Resistance Point 127.45
Last Price 126.92
1st Support Level 126.61
2nd Support Level 126.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.